NCT00144222View on ClinicalTrials.gov

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Hypertension
Interventions
DRUG

Telmisartan 40 mg/HCTZ 12.5 mg

DRUG

Telmisartan 40 mg

Trial Locations (2)

060-0003

Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

163-6003

Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY